Skip to main content

Oruka Therapeutics, Inc.

corporate_fare Company Profile

Oruka Therapeutics, Inc.

ORKA·NASDAQ·Life Sciences·CIK 0000907654

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops new monoclonal antibody treatments for psoriasis (PsO) and other inflammatory and immunology (I&I) conditions. The company's name, derived from the words for "skin" and "restoration," reflects its mission to provide therapies for chronic skin diseases that offer patients significant relief. The company's strategy involves using antibody engineering and format innovations on established mechanisms of action. This approach aims to enhance the effectiveness and dosing schedules of existing standard-of-care medicines while reducing technical and biological risks. Oruka Therapeutics' programs focus on treating and potentially modifying diseases by targeting mechanisms with proven efficacy and safety that are involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Oruka Therapeutics' lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company completed its acquisition of Pre-Merger Oruka on August 29, 2024. Pre-Merger Oruka was a pre-clinical stage biotechnology company incorporated on February 6, 2024, to hold rights to intellectual property developed by Paragon Therapeutics, Inc. On August 29, 2024, ARCA biopharma, Inc. changed its name to Oruka Therapeutics, Inc. and its Nasdaq ticker symbol from "ABIO" to "ORKA".

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ORKA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-26, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for ORKA spans S-3, 8-K, 144, 4.

Recent high-impact activity:

  • ORKA-001 Hits 61% Complete Skin Clearance at Week 16 in Phase 2b Psoriasis Trial
  • ORKA-001 Week 28 Data Shows Deepening Psoriasis Clearance Without Additional Dosing
  • Oruka Upsizes ATM to $500M and Files $1B Universal Shelf
  • Oruka Reports Q2 2026 Results, $1.1B Cash, and Multiple Near-Term Catalysts
  • Major Investor & Director Files Intent to Sell $300M in Oruka Therapeutics Stock

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$105.43M
Op. Cash Flow
-$88.21M
Free Cash Flow
-$88.42M
Operating Income
-$122.05M
Cash & Equivalents
$46.94M
Debt / Equity
0.00×
Shares Outstanding
48.72M sh
Source: 10-K · filed 2026-03-12 · accession 0001213900-26-026929

Short Interest & Short Volume

7.06 days to cover

FINRA reported short interest of 6,464,212 shares in ORKA as of the October 30, 2026 settlement, a 5.8% increase from the prior period — about 7.1 days to cover at its recent average daily volume. On November 20, 2026, 26.9% of ORKA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)6,464,212 shares as of October 30, 2026
Change vs prior period▲ 5.8%
Days to cover7.06 at avg daily volume of 915,065
Daily short volume (FINRA facilities)26.9% of 990,523 shares on November 20, 2026
5-day average short volume37.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for ORKA, detected from its recent SEC filings · based on capital-structure filings through 2026-08-28.

1 recent capital raiseATM program1 shelf registration

ATM Program Prospectus Filed · Offering Terms Unchanged

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with O →
$95.81
52-week range · as of 2026-08-21 $14.1 – $115.52
Market cap
$6.5B
Volume
2M (2.0× avg)
3-mo avg 983.5K
Live data · 2026-11-22 08:37 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ORKA - Latest Insights

ORKA
Oct 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $78.00
Real-time Price: $95.81 info
Change: +$17.81 (+23%) info
Market Cap: $6.498B info
ORKA
Sep 23, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $96.00
Real-time Price: $95.81 info
Change: -$0.190 (-0.20%) info
Market Cap: $6.498B info
ORKA
Aug 21, 2026, 4:18 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $107.96
Real-time Price: $95.81 info
Change: -$12.15 (-11%) info
Market Cap: $6.498B info
ORKA
Aug 10, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $98.51
Real-time Price: $95.81 info
Change: -$2.70 (-3%) info
Market Cap: $6.498B info
ORKA
Jul 01, 2026, 9:31 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $86.07
Real-time Price: $95.81 info
Change: +$9.74 (+11%) info
Market Cap: $6.498B info
ORKA
Jul 01, 2026, 9:30 PM EDT
Filing Type: 4
Importance Score:
9
Price at Filing: $86.07
Real-time Price: $95.81 info
Change: +$9.74 (+11%) info
Market Cap: $6.498B info
ORKA
Jul 01, 2026, 9:30 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $86.07
Real-time Price: $95.81 info
Change: +$9.74 (+11%) info
Market Cap: $6.498B info
ORKA
Jun 01, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $55.01
Real-time Price: $95.81 info
Change: +$40.80 (+74%) info
Market Cap: $6.498B info
ORKA
May 21, 2026, 4:32 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $58.70
Real-time Price: $95.81 info
Change: +$37.11 (+63%) info
Market Cap: $6.498B info
ORKA
May 13, 2026, 4:06 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $63.18
Real-time Price: $95.81 info
Change: +$32.63 (+52%) info
Market Cap: $6.498B info
ORKA
May 13, 2026, 4:01 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $63.18
Real-time Price: $95.81 info
Change: +$32.63 (+52%) info
Market Cap: $6.498B info
ORKA
Apr 29, 2026, 4:55 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $68.00
Real-time Price: $95.81 info
Change: +$27.81 (+41%) info
Market Cap: $6.498B info
ORKA
Apr 28, 2026, 7:44 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $74.30
Real-time Price: $95.81 info
Change: +$21.51 (+29%) info
Market Cap: $6.498B info
ORKA
Apr 27, 2026, 5:22 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $79.08
Real-time Price: $95.81 info
Change: +$16.73 (+21%) info
Market Cap: $6.498B info
ORKA
Apr 27, 2026, 5:22 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $79.08
Real-time Price: $95.81 info
Change: +$16.73 (+21%) info
Market Cap: $6.498B info
ORKA
Apr 27, 2026, 4:17 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $76.14
Real-time Price: $95.81 info
Change: +$19.67 (+26%) info
Market Cap: $6.498B info
ORKA
Apr 27, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $86.73
Real-time Price: $95.81 info
Change: +$9.08 (+10%) info
Market Cap: $6.498B info
ORKA
Apr 27, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $101.79
Real-time Price: $95.81 info
Change: -$5.98 (-6%) info
Market Cap: $6.498B info
ORKA
Apr 10, 2026, 5:28 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $59.58
Real-time Price: $95.81 info
Change: +$36.23 (+61%) info
Market Cap: $6.498B info
ORKA
Apr 02, 2026, 4:05 PM EDT
Filing Type: S-3
Importance Score:
8
Price at Filing: $53.20
Real-time Price: $95.81 info
Change: +$42.61 (+80%) info
Market Cap: $6.498B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets